Blood glucose modulation

"Blood glucose modulation" is not a single molecule or canonical therapeutic target but rather describes the complex physiological process by which the body maintains appropriate levels of circulating blood sugar. This process involves multiple organs—primarily the pancreas, liver, muscle tissue—and numerous hormones including insulin and glucagon[2][4][8]. Key molecular players include:\n\n• **Insulin**—a peptide hormone produced by pancreatic β-cells that lowers blood glucose by promoting cellular uptake via GLUT4 transporters in muscle and adipose tissue[2][3][5].\n• **Glucagon**—a peptide hormone from pancreatic α-cells that raises blood sugar by stimulating hepatic glycogenolysis and gluconeogenesis[4].\n• **Incretins** such as GLP‑1 and GIP—which enhance insulin secretion postprandially through G protein–coupled receptors on β-cells[5].\n• **Glucose transporters**—including GLUT1–GLUT4 proteins responsible for tissue-specific uptake of circulating glucose[2][5].\n\nTherapeutic interventions in diabetes often target these pathways using agents like insulin analogues; GLP‑1 receptor agonists; DPP‑4 inhibitors; SGLT2 inhibitors; sulfonylureas; thiazolidinediones—all acting at different points within this regulatory network.\n\nBecause "blood glucose modulation" refers to an integrated physiological system rather than a discrete druggable entity or defined macromolecule/receptor/enzyme/transporter/protein complex, it should not be considered a canonical therapeutic target. Instead, individual components within this system serve as true drug targets—for example: "Insulin receptor," "Glucagon-like peptide 1 receptor," "Sodium-glucose cotransporter 2," etc.[3][6].\n\nIf you require structured information about actual druggable targets involved in blood glucose regulation/modulation—for instance “Insulin receptor” or “GLP‑1 receptor”—please specify one such molecule.

Other names

Blood glucose regulationGlucose homeostasisRegulation of blood sugar